We developed an ultrasensitive 
Another difficulty associated with PSA assays is the lack of a universally acceptable standard preparation (24). The current commercial kit standards are based on human serum or synthetic matrices with bovine serum albumin (BSA) and contain added PSA isolated from human seminal plasma.
Thus, the various PSA subfractions in the standards are potentially different from those in the serum. These differences may lead to different patients' results because monoclonal and (or) polyclonal antibodies recognize the PSA subfractions with different affinities (21, 22) . One way to minimize the problem is to adjust the assays to match the results of the Hybritech (San Diego, CA) Tandem"-PSA kit, which is widely used and established in the field (16, 19). However, good correlation between assays does not necessarily mean that the same PSA subfractions are measured, because the correlation between free and bound PSA is reasonably good (21).
Graves (19) and Vessella et al. (16) stressed the importance of new highly sensitive PSA assays that can be used to monitor prostate cancer patients after radical prostatectomy.
Such assays, which should be capable of detecting at least 0.1 giL PSA, have already proved useful for detecting early relapse (15, 16, 19) . Currently, the most sensitive PSA assay (16, 17) has an analytical lowest limit of detection of 0.03 p.g/L and a biological detection limit of 0.06-0.1 pg/L. Here we describe the development of a new PSA assay based on the use of monoclonal and polyclonal antibodies and enzymatically amplified time-resolved immunofluorometry with terbium chelates. The method correlates well with the established Hybritech assay. The analytical limit of detection is 0.002 1gfL, the lowest reported for this analyte.
With this assay, we were able to quantify PSA concentrations in serum of patients after prostatectomy.
Materials and Methods

Instrumentation.
For 
Results
Assay optimization.
To attain the highest possible sensitivity, during the initial stages of assay development we considered various combinations of commerdaily available monoclonal and polyclonal antibodies.
The pair we selected gave the most sensitive and accurate results. All diluents were optimized for protein, salt, goat or mouse serum, and detergent presence and concentration, to obtain the highest possible signal and the lowest possible background, and at the same time eliminate or minimize the effect of heterophile antibodies. Human anti-goat antibodies, present in some patients' sera and interfering with earlier versions of this assay, were effectively eliminated with use of the biotin-streptavidin system and the reagents described. Likewise, all antibody amounts were carefully optimized, along with the incubation times and temperature (25 #{176}C vs 37#{176}C). Although it was possible to perform the assay by incubating the monoclonal and polyclonal antibodies with the sample in one step, we did not because this reduced the sensitivity -5-10-fold, and we also wanted to avoid the high-dose hook effect. We tried to directly conjugate the polyclonal antibody to ALP, but this reduced the sensitivity 5-10-fold in comparison to our final optimized assay.
Calibration
curves. Representative calibration curves for the proposed assay are shown in Figure 1 . With 50-/LL sample volumes, the curve is useful for PSA quantification up to 10 g/L. We also used sample volumes of 25, 10, and 5 j.&Land extended the assay range to 25, 50, and 100 j&g/L, respectively, without changing any other assay conditions. All other data reported in this paper were generated with 50-L sample volumes. repeated by adding PSA from the sera of two men with prostate cancer to sera from two women and one postprostatectomy man, the recovery was closeto the theoretically expected recovery (mean = 106% ± 7%, n = 12) 
